Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand ...

Analyst recommends Novartis as a Buy for long-term investors, BioAge a Hold, following strategic partnership for age-related ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geoff Meacham ...

Michael Ulz, an analyst from Morgan Stanley, maintained the Buy rating on Fractyl Health, Inc. (GUTS – Research Report). The associated price ...

Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, ...

Eli Lilly (LLY) stock fell as its obesity therapy tirzepatide missed forecasts, amid focus on compounded weight loss ...

Hims & Hers reported impressive third-quarter results in November, with earnings of 32 cents per share, far exceeding analyst ...

As certain weight-loss drugs have become increasingly popular, scammers are taking notice and coming out of the woodwork to ...

People are being “overdiagnosed” with obesity, leading medics have warned as they called for a “reframing” of the way the ...

On Jan. 1, North Dakota became the first state in the country where access to drugs like Wegovy is part of the EHB package. About 55,293 of North Dakota's 784,000 residents had coverage through fully ...